# Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

> **NCT00909025** · PHASE1 · COMPLETED · sponsor: **Ganymed Pharmaceuticals GmbH** · enrollment: 15 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Claudiximab

## Key facts

- **NCT ID:** NCT00909025
- **Lead sponsor:** Ganymed Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-31
- **Primary completion:** 2010-05-31
- **Final completion:** 2010-05-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00909025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00909025, "Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00909025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*